Positron Emission Tomography Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer

https://t.co/4gYD3NGtLb

RT @JAMAOnc: https://t.co/eiiupVuaAf

RT @JAMAOnc: https://t.co/eiiupVuaAf

RT @JAMAOnc: https://t.co/eiiupVuaAf

Positron Emission Tomography Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer: A Nonrandomized Clinical Trial | Breast Cancer | JAMA Oncology | JAMA Network https://t.co/vdUCyxsspC

RT @JAMAOnc: PET imaging of PARP-1 in breast cancer demonstrates high variability of expression within tumor subtypes and is a potential PA…

RT @JAMAOnc: https://t.co/eiiupVuaAf

https://t.co/eiiupVuaAf

RT @JAMAOnc: PET imaging of PARP-1 in breast cancer demonstrates high variability of expression within tumor subtypes and is a potential PA…

PET imaging of PARP-1 in breast cancer demonstrates high variability of expression within tumor subtypes and is a potential PARP inhibitor biomarker https://t.co/AQRxPPs6kR

RT @SusanGKomen: Komen-funded researcher Dr. McDonald’s new @JAMAOnc publication shows that PARP imaging probes may identify patients likel…

Komen-funded researcher Dr. McDonald’s new @JAMAOnc publication shows that PARP imaging probes may identify patients likely to respond to PARP inhibitor drugs. https://t.co/EIhIbsXYOl

New from @PennRadiology #ICYMI

Great news on more @SusanGKomen-funded research, being lead by Career Catalyst researcher, Dr. McDonald—who leads our first online discussion series May 13 (see our website for details)

Yeah, Elizabeth!!

https://t.co/qxrBEvYBgD

RT @PennMedNews: Findings from a new @JAMAOnc study led by @PennRadiology professor Elizabeth McDonald supports PET imaging of PARP-1 expre…

RT @PennMedNews: Findings from a new @JAMAOnc study led by @PennRadiology professor Elizabeth McDonald supports PET imaging of PARP-1 expre…

Findings from a new @JAMAOnc study led by @PennRadiology professor Elizabeth McDonald supports PET imaging of PARP-1 expression as a companion diagnostic for select breast cancer patients. https://t.co/0vdPMGYc7J

RT @VivekSubbiah: PET Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer https://t.co/rPYpTMHzad

PET Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer https://t.co/rPYpTMHzad

RT @NatureCancer: Published in @JAMAOnc: radiolabeleld PARPi PET imaging using [18F]FTT in breast cancer patients across different subtypes…

Published in @JAMAOnc: radiolabeleld PARPi PET imaging using [18F]FTT in breast cancer patients across different subtypes to identify responders to this #cancer #therapy https://t.co/K9aNqd2nGz #WeekendReads #NatureCancerPicks https://t.co/krizLhdYQM

RT @cdanicas: [18F]FTT tracer uptake was independent of breast cancer subtype! https://t.co/DES2pe0I24

RT @PennRadiology: Great @PennMedicine team effort on clinical trial shows PARP-1 expression is independent of breast cancer subtype provid…

PCGI Investigators Dr. David Mankoff and Elizabeth McDonald led a multidisciplinary team of PennMed researchers to show PARP-1 expression is independent of breast cancer subtype, providing foundational evidence to test PARP PET: https://t.co/nQnTM8VLlf

RT @PennRadiology: Great @PennMedicine team effort on clinical trial shows PARP-1 expression is independent of breast cancer subtype provid…

RT @RHMachLab: RT @PennRadiology PARP-1 tracer demonstrates that PARP-1 expression is independent of breast cancer subtype providing founda…

RT @PennRadiology PARP-1 tracer demonstrates that PARP-1 expression is independent of breast cancer subtype providing foundational evidence to test PARP PET as a companion diagnostic for PARP inhibitor therapy https://t.co/2h8NHfWvPQ

RT @PennRadiology: Great @PennMedicine team effort on clinical trial shows PARP-1 expression is independent of breast cancer subtype provid…

RT @_SOLTI: 📣A prospective nonrandomized trial supports measuring PARP-1 expression using a radiolabeled PARP inhib. It demonstrates PARP i…

RT @_SOLTI: 📣A prospective nonrandomized trial supports measuring PARP-1 expression using a radiolabeled PARP inhib. It demonstrates PARP i…

RT @_SOLTI: 📣A prospective nonrandomized trial supports measuring PARP-1 expression using a radiolabeled PARP inhib. It demonstrates PARP i…

📣A prospective nonrandomized trial supports measuring PARP-1 expression using a radiolabeled PARP inhib. It demonstrates PARP inhibitor drug efficacy in individuals with different #breastcancer subtypes bearing BRCA1/2 pathogenic variants. 🔗https://t.co/3

RT @NatRevClinOncol: In a study of [18F]FTT, a radiolabelled PARP inhibitor, for quantification of PARP-1, PARP-1 expression was found to…

In a study of [18F]FTT, a radiolabelled PARP inhibitor, for quantification of PARP-1, PARP-1 expression was found to be highly variable in breast cancer, with a similar range of [18F]FTT uptake seen in BRCA pathogenic variant carriers & noncarriers: h

RT @JAMAOnc: [18F]FluorThanatrace ([18F]FFT) is a radiolabeled PARP inhibitor that was tested for imaging in 30 women w/#BreastCancer, show…

RT @JAMAOnc: [18F]FluorThanatrace ([18F]FFT) is a radiolabeled PARP inhibitor that was tested for imaging in 30 women w/#BreastCancer, show…

[18F]FluorThanatrace ([18F]FFT) is a radiolabeled PARP inhibitor that was tested for imaging in 30 women w/#BreastCancer, showing in vivo PARP-1 expression to be highly variable in this setting, supporting PET imaging to quantitate PARP-1 expression https:

[18F]FTT tracer uptake was independent of breast cancer subtype! https://t.co/DES2pe0I24

RT @DrMHofman: https://t.co/V8Nt0kVXbY

https://t.co/V8Nt0kVXbY

An update on #PARPinhibitor expression. #breastcancer

RT @MamMa_mimumemo: JAMA Oncolから 乳癌や卵巣癌で使われるPARP阻害薬のターゲットであるPARP1。 これの発現とPARP阻害薬の効果に相関があることがin vitroの研究では言われていて、これに放射性同位体をくっつけたいわば”PARP-PET…

RT @JAMAOnc: PET imaging of PARP-1 in breast cancer demonstrates high variability of expression within tumor subtypes and is a potential PA…

RT @PennRadiology: Great @PennMedicine team effort on clinical trial shows PARP-1 expression is independent of breast cancer subtype provid…

RT @KMaxwellLab: Honored that my lab could contribute the genomics for study of this promising radiotracer based diagnostic for PARPi @Bass…

RT @JAMAOnc: PET imaging of PARP-1 in breast cancer demonstrates high variability of expression within tumor subtypes and is a potential PA…

RT @PennRadiology: Great @PennMedicine team effort on clinical trial shows PARP-1 expression is independent of breast cancer subtype provid…

PET imaging of PARP-1 in breast cancer demonstrates high variability of expression within tumor subtypes and is a potential PARP inhibitor biomarker https://t.co/DJxPiyNAMd

RT @PennRadiology: Great @PennMedicine team effort on clinical trial shows PARP-1 expression is independent of breast cancer subtype provid…

RT @KMaxwellLab: Honored that my lab could contribute the genomics for study of this promising radiotracer based diagnostic for PARPi @Bass…

PET Imaging of Poly–(Adenosine Diphosphate–Ribose) Polymerase 1 Expression in Breast Cancer https://t.co/Dxy3zgkESZ

https://t.co/DfPJGlj7i9

Honored that my lab could contribute the genomics for study of this promising radiotracer based diagnostic for PARPi @BasserBRCA

JAMA Oncolから 乳癌や卵巣癌で使われるPARP阻害薬のターゲットであるPARP1。 これの発現とPARP阻害薬の効果に相関があることがin vitroの研究では言われていて、これに放射性同位体をくっつけたいわば”PARP-PET”で、PARP阻害薬の効果を予測できるようになるかもという報告。 https://t.co/hJ1FWZsW0t

RT @PennRadiology: Great @PennMedicine team effort on clinical trial shows PARP-1 expression is independent of breast cancer subtype provid…

Great @PennMedicine team effort on clinical trial shows PARP-1 expression is independent of breast cancer subtype providing foundational evidence to test PARP PET as a companion diagnostic for PARP inhibitor therapy https://t.co/jqo0IUZomI #PARP1 #breastca